{"nctId":"NCT00235391","briefTitle":"Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload","startDateStruct":{"date":"2005-10"},"conditions":["Thalassemia","Sickle Cell Disease","Diamond Blackfan Anemia","Myelofibrosis"],"count":1683,"armGroups":[{"label":"Deferasirox","type":"EXPERIMENTAL","interventionNames":["Drug: Deferasirox"]}],"interventions":[{"name":"Deferasirox","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female patients greater than or equal to 2 years of age\n* Documented congenital disorder of red blood cells (e.g., β-thalassemia major, sickle cell anemia, diamond-blackfan anemia) requiring ongoing blood transfusions\n* Cannot be adequately treated with a locally approved iron chelator due to one of the following reasons:\n\n  * Documented non-compliance, defined as having taken less than 50% of the prescribed chelation therapy doses in the 12 months prior to study entry\n  * Contraindications, unacceptable toxicities and/or documented poor response to locally approved iron chelators despite proper compliance\n* History of at least 20 blood transfusions (equivalent to 100 mL/kg of packed red blood cells (PRBC\\])\n* Serum ferritin value greater than or equal to 1000 µg/L\n* Ability to comply with all study-related procedures, medications, and evaluations\n\nExclusion Criteria:\n\n* Ongoing treatment with another iron chelator (Any other iron chelation therapy must be discontinued at least 24 hours prior to study entry.)\n* Patients who meet the eligibility criteria for any other ongoing Novartis sponsored clinical study protocol with deferasirox and who have geographic access to these sites\n* Patients unable to tolerate (or who have unacceptable toxicities to) prior treatment with deferasirox\n* Serum creatinine above the upper limit of normal at screening.\n* Patients with ALT ≥ 500 U/L at screening.\n* Evidence of chelation-related cataracts or hearing loss within 4 weeks prior to baseline\n* Pregnancy (as indicated by serum β-HCG pregnancy test at screening for all female patients with the potential to become pregnant) and patients who are breastfeeding\n* Patients treated with systemic investigational drug within 4 weeks prior to or with topical investigational drug within 7 days prior to the baseline visit\n\nOther protocol-defined inclusion/exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"2 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Safety Profile of Deferasirox Based Upon Drug Administration and Reporting of Serious Adverse Events","description":"Safety as assessed by the number of participants with death, serious adverse events (SAE), and/or Adverse Events (AEs) leading to study drug interruption or discontinuation. Note: only treatment emergent AEs are summarized.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"4","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"22","spread":null},{"groupId":"OG002","value":"27","spread":null},{"groupId":"OG003","value":"129","spread":null},{"groupId":"OG004","value":"4","spread":null},{"groupId":"OG005","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"10","spread":null},{"groupId":"OG003","value":"75","spread":null},{"groupId":"OG004","value":"5","spread":null},{"groupId":"OG005","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"31","spread":null},{"groupId":"OG002","value":"28","spread":null},{"groupId":"OG003","value":"209","spread":null},{"groupId":"OG004","value":"11","spread":null},{"groupId":"OG005","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"The Change in Serum Ferritin Values From Baseline Through Completion of the Study","description":"The number of participants with Improvement, No Change or Worsening in Serum ferritin category levels at the end of the study compared to baseline. Serum ferritin levels in µg/L were divided into to 6 categories: (\\<1000), (1000-\\<2500), (2500-\\<4000), (4000-\\<5500), (5500-\\<7000) and (\\>=7000). Improvement was defined as a shift to a lower category at the end of study compared to the category at baseline. Worsening was defined as a shift to a higher category at the end of the study compared to the category at baseline. No change was no change in category at end of study from baseline.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"27","spread":null},{"groupId":"OG002","value":"26","spread":null},{"groupId":"OG003","value":"206","spread":null},{"groupId":"OG004","value":"4","spread":null},{"groupId":"OG005","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63","spread":null},{"groupId":"OG001","value":"106","spread":null},{"groupId":"OG002","value":"87","spread":null},{"groupId":"OG003","value":"570","spread":null},{"groupId":"OG004","value":"31","spread":null},{"groupId":"OG005","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"63","spread":null},{"groupId":"OG002","value":"55","spread":null},{"groupId":"OG003","value":"341","spread":null},{"groupId":"OG004","value":"7","spread":null},{"groupId":"OG005","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":194,"n":1683},"commonTop":["Rash"]}}}